Astria Therapeutics, Inc. (ATXS)

Market Cap	718.13M +50.2%
Revenue (ttm)	706,000
Net Income	-124.03M
EPS	-2.14
Shares Out	57.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,199,309
Open	12.48
Previous Close	n/a
Day's Range	12.45 - 12.59
52-Week Range	3.56 - 13.29
Beta	0.02
Analysts	Hold
Price Target	24.33 (+93.4%)
Earnings Date	Mar 10, 2026

About ATXS

Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder assoc...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 25, 2015
• Employees: 78
• Stock Exchange: NASDAQ
• Ticker Symbol: ATXS
• Website: https://www.astriatx.com

Analyst Summary

According to 6 analysts, the average rating for ATXS stock is "Hold." The 12-month stock price target is $24.33, which is an increase of 93.40% from the latest price.

Price Target

$24.33

(93.40% upside)

Analyst Consensus: Hold